<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5c3580ce-c509-4ab6-9238-85503c609119"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use VANCOMYCIN HYDROCHLORIDE FOR INJECTION safely and effectively. See full prescribing information for VANCOMYCIN HYDROCHLORIDE FOR INJECTION.</content>
      <br/>
      <br/>
      <content styleCode="bold">VANCOMYCIN HYDROCHLORIDE for injection, for intravenous use </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1958</content>
   </title>
   <effectiveTime value="20250321"/>
   <setId root="b62b7190-48e8-4596-a6ad-9ad455e5c8c6"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="001230762" root="1.3.6.1.4.1.519.1"/>
            <name>Hikma Pharmaceuticals USA Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="62fa1435-dd01-4dc9-8104-713aa9afa4be"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250321"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0143-9152" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Vancomycin Hydrochloride</name>
                        <formCode code="C42957" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Vancomycin Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="1.25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="71WO621TJD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VANCOMYCIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="6Q205EH1VU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VANCOMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" displayName="VIAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0143-9152-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230717"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217489" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230717"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0143-9153" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Vancomycin Hydrochloride</name>
                        <formCode code="C42957" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Vancomycin Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="1.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="71WO621TJD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VANCOMYCIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="6Q205EH1VU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VANCOMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" displayName="VIAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0143-9153-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230717"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217489" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230717"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_89e216a7-8b92-49d4-ada0-96ac04abc313">
               <id root="d4d6a333-8c11-42f5-9750-5ea58fd42d83"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <content styleCode="bold">These highlights do not include all the information needed to use VANCOMYCIN HYDROCHLORIDE FOR INJECTION safely and effectively. See full prescribing information for VANCOMYCIN HYDROCHLORIDE FOR INJECTION.</content>
                  <br/>
                  <br/>
                  <content styleCode="bold">VANCOMYCIN HYDROCHLORIDE for injection, for intravenous use </content>
                  <br/>
                  <content styleCode="bold">Initial U.S. Approval: 1958<br/>
                  </content>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection is a glycopeptide antibacterial indicated in adult and pediatric patients (neonates and older) for the treatment of:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Septicemia (<linkHtml href="#LINK_ed2a1458-2d68-42bb-88d2-3e82544b377b">1.1</linkHtml>)</item>
                           <item>Infective Endocarditis (<linkHtml href="#LINK_b7553066-1acf-4c9c-9cb2-1ccfda7396be">1.2</linkHtml>)</item>
                           <item>Skin and Skin Structure Infections (<linkHtml href="#LINK_6d1485a4-e937-4954-87d1-c0727b4db84c">1.3</linkHtml>)</item>
                           <item>Bone Infections (<linkHtml href="#LINK_e0f8c36b-c5d3-4e3c-b829-85810977ac9e">1.4</linkHtml>)</item>
                           <item>Lower Respiratory Tract Infections (<linkHtml href="#LINK_e285b228-2915-4c1c-9495-8cf4695f2316">1.5</linkHtml>)</item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride for injection and other antibacterial drugs, vancomycin hydrochloride for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (<linkHtml href="#LINK_921baa67-d1b3-4cff-b82d-db170b788095">1.6</linkHtml>)<br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_ed2a1458-2d68-42bb-88d2-3e82544b377b">
                     <id root="65c8c79c-c0ee-4310-8ab4-b0491d32a1a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.1 Septicemia</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection is indicated in adults and pediatric patients (neonates and older) for the treatment of septicemia due to:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Susceptible isolates of methicillin-resistant <content styleCode="italics">Staphylococcus aureus </content>(MRSA) and coagulase negative staphylococci.</item>
                           <item>Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b7553066-1acf-4c9c-9cb2-1ccfda7396be">
                     <id root="4e055127-7257-4647-9256-b84895fd728d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.2 Infective Endocarditis</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection is indicated in adults and pediatric patients (neonates and older) for the treatment of infective endocarditis due to:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Susceptible isolates of MRSA.</item>
                           <item>Viridans group streptococci <content styleCode="italics">Streptococcus gallolyticus </content>(previously known as <content styleCode="italics">Streptococcus bovis</content>), <content styleCode="italics">Enterococcus </content>species and <content styleCode="italics">Corynebacterium </content>species. For enterococcal endocarditis, use vancomycin hydrochloride for injection in combination with an aminoglycoside.</item>
                           <item>Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.</item>
                        </list>
                        <paragraph>Vancomycin hydrochloride for injection is indicated in adults and pediatric patients (neonates and older) for the treatment of early-onset prosthetic valve endocarditis caused by <content styleCode="italics">Staphylococcus epidermidis </content>in combination with rifampin and an aminoglycoside.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6d1485a4-e937-4954-87d1-c0727b4db84c">
                     <id root="81c99cdb-1cf1-4810-9b05-73c0f59a5453"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.3 Skin and Skin Structure Infections</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection is indicated in adults and pediatric patients (neonates and older) for the treatment of skin and skin structure infections due to:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Susceptible isolates of MRSA and coagulase negative staphylococci.</item>
                           <item>Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e0f8c36b-c5d3-4e3c-b829-85810977ac9e">
                     <id root="62376026-04fa-4ad8-86be-a2bfc9f9e0b3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.4 Bone Infections</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection is indicated in adults and pediatric patients (neonates and older) for the treatment of bone infections due to:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Susceptible isolates of MRSA and coagulase negative staphylococci.</item>
                           <item>Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e285b228-2915-4c1c-9495-8cf4695f2316">
                     <id root="4d4ead36-1ae3-47dc-8e0c-16264806582e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.5 Lower Respiratory Tract Infections</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection is indicated in adults and pediatric patients (neonates and older) for the treatment of lower respiratory tract infections due to:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Susceptible isolates of MRSA</item>
                           <item>Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_921baa67-d1b3-4cff-b82d-db170b788095">
                     <id root="3701bfa1-9008-42ca-b868-202511fc7537"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.6 Usage</content>
                     </title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride for injection and other antibacterial drugs, vancomycin hydrochloride for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_85590813-5e0e-4242-a548-b5a0b528e548">
               <id root="fcc0fcd4-a8f8-4551-b0ec-ab835c061d78"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 DOSAGE AND ADMINISTRATION</content>
               </title>
               <text/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Administer vancomycin hydrochloride for injection in a diluted solution over 60 minutes or greater to reduce the risk of infusion reactions.</item>
                           <item>See full prescribing information for further important administration and preparation instructions (<linkHtml href="#LINK_0da61447-6b4f-4927-bdf0-b8af6404cc55">2.1</linkHtml>, <linkHtml href="#LINK_7c26d99c-9549-4eb7-9392-3298280aa787">2.5</linkHtml>)</item>
                           <item>Adult Patients: 2 g divided either as 0.5 grams (g) every 6 hours or 1 g every 12 hours (<linkHtml href="#LINK_72f5c693-5c78-4203-8149-1c67678ab3af">2.2</linkHtml>)</item>
                           <item>Pediatric Patients (1 month and older): 10 mg/kg per dose given every 6 hours (<linkHtml href="#LINK_8a3d22c7-1ec1-4174-ba90-3a24d19d439a">2.3</linkHtml>)</item>
                           <item>Neonates: See full prescribing information for recommended doses in neonates (<linkHtml href="#LINK_8a3d22c7-1ec1-4174-ba90-3a24d19d439a">2.3</linkHtml>)</item>
                           <item>Patients with renal impairment: See full prescribing information for recommended doses in patients with renal impairment (<linkHtml href="#LINK_43d36673-09ca-4fa4-8374-e3e9d9c556f5">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_0da61447-6b4f-4927-bdf0-b8af6404cc55">
                     <id root="0ea5238f-a954-4f4d-93e1-e14e193b4b6b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 Important Administration Instructions</content>
                     </title>
                     <text>
                        <paragraph>To reduce the risk of infusion related adverse reactions, administer vancomycin hydrochloride for injection in a diluted solution over 60 minutes or greater <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_e2101373-36c3-4ee8-894f-dc3993354b7a">Warnings and Precautions (5.1)</linkHtml> </content>and <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_83df8d85-6787-48b9-98c0-f3e07bb0dffa">Adverse Reactions (6.1)</linkHtml>]</content>. Vancomycin hydrochloride for injection concentrations of no more than 5 mg/mL are recommended in adults <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_72f5c693-5c78-4203-8149-1c67678ab3af">Dosage and Administration (2.2)</linkHtml>]. </content>See also age- specific recommendations <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_8a3d22c7-1ec1-4174-ba90-3a24d19d439a">Dosage and Administration (2.3)</linkHtml>]</content>. In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_e2101373-36c3-4ee8-894f-dc3993354b7a">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Administer vancomycin hydrochloride for injection prior to intravenous anesthetic agents to reduce the risk of infusion related adverse reactions <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_e2101373-36c3-4ee8-894f-dc3993354b7a">Warnings and Precautions (5.1)</linkHtml>].</content>
                           <br/>
                        </paragraph>
                        <paragraph>Administer vancomycin hydrochloride by a secure intravenous route of administration to avoid local irritation and phlebitis reactions <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_5ac76dfd-5b9a-4154-a902-88a36d5afd1f">Warnings and Precautions (5.8)</linkHtml>]</content>.<br/>
                        </paragraph>
                        <paragraph>The supplied lyophilized powder must be reconstituted and subsequently diluted prior to intravenous use <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_7c26d99c-9549-4eb7-9392-3298280aa787">Dosage and Administration (2.5)</linkHtml>].</content>
                           <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_72f5c693-5c78-4203-8149-1c67678ab3af">
                     <id root="98851903-1b77-41ee-bae5-50fcaed7bc39"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 Dosage in Adult Patients With Normal Renal Function</content>
                     </title>
                     <text>
                        <paragraph>The usual daily intravenous dose is 2 grams divided either as 500 mg every 6 hours or 1 g every 12 hours. Administer each dose over a period of 60 minutes or greater. Other patient factors, such as age or obesity, may call for modification of the usual intravenous daily dose.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8a3d22c7-1ec1-4174-ba90-3a24d19d439a">
                     <id root="e836d916-28a1-48a7-9201-2107bebd74d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 Dosage in Pediatric Patients With Normal Renal Function</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (Aged 1 month and older)</content>
                        </paragraph>
                        <paragraph>The usual intravenous dosage of vancomycin is 10 mg/kg per dose given every 6 hours. Each dose should be administered over a period of at least 60 minutes. Close monitoring of serum concentrations of vancomycin may be warranted in these patients.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Neonates (Up to 1 month old</content>)<br/>
                        </paragraph>
                        <paragraph>In pediatric patients, up to the age of 1 month, the total daily intravenous dosage may be lower. In neonates, an initial dose of 15 mg/kg is suggested, followed by 10 mg/kg every 12 hours for neonates in the 1<sup>st</sup> week of life and every 8 hours thereafter up to the age of 1 month. Each dose should be administered over 60 minutes. In premature infants, vancomycin clearance decreases as postconceptional age decreases. Therefore, longer dosing intervals may be necessary in premature infants. Close monitoring of serum concentrations of vancomycin is recommended in these patients.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_43d36673-09ca-4fa4-8374-e3e9d9c556f5">
                     <id root="336c103b-ef4c-43d6-ac32-7fc2875e0a73"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.4 Dosage in Patients With Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>Dosage adjustment must be made in patients with renal impairment. The initial dose should be no less than 15 mg/kg, in patients with any degree of renal impairment.</paragraph>
                        <paragraph>In premature infants and the elderly, greater dosage reductions than expected may be necessary because of decreased renal function. Measure trough vancomycin serum concentrations to guide therapy, especially in seriously ill patients with changing renal function.<br/>
                        </paragraph>
                        <paragraph>For functionally anephric patients, an initial dose of 15 mg/kg of body weight should be given to achieve prompt therapeutic serum concentration. A dose of 1.9 mg/kg/24 hr should be given after the initial dose of 15 mg/kg.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7c26d99c-9549-4eb7-9392-3298280aa787">
                     <id root="e968ace6-f230-46c2-b812-e67e1630630c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.5 Preparation of Vancomycin Hydrochloride for Injection for Intravenous Administration and Storage Instructions</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection must be reconstituted and further diluted. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Reconstitution of the Lyophilized Powder and further dilution</content>
                        </paragraph>
                        <paragraph>At the time of use, reconstitute the vials of vancomycin hydrochloride for injection (lyophilized powder) with Sterile Water for Injection to a concentration of 50 mg of vancomycin/mL then further dilute with an infusion solution to a final concentration of 5 mg/mL (see Table 1 for the appropriate volumes). Discard any reconstituted solution remaining in the vial.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1 Volume of Sterile Water for Injection to be Added for Reconstitution and Volume of Infusion Solution to be Used for Further Dilution</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="1">
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="underline">Vancomycin Strength per Vial</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="underline">Volume of Sterile Water for</content>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="underline">Injection for reconstitution</content>
                                       </content>
                                       <content styleCode="bold">
                                          <content styleCode="underline">
                                             <sup>a</sup>
                                          </content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="underline">Volume of infusion solution</content>
                                       </content>
                                       <content styleCode="underline">
                                          <content styleCode="bold">
                                             <sup>b </sup>
                                          </content>
                                       </content>
                                       <content styleCode="bold">
                                          <content styleCode="underline">to further dilute to a final </content>
                                          <content styleCode="underline">concentration of</content>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="underline">5 mg/mL</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>                          1.25 g</paragraph>
                                 </td>
                                 <td>
                                    <paragraph>25 mL</paragraph>
                                 </td>
                                 <td>
                                    <paragraph>                              250 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>                           1.5 g</paragraph>
                                 </td>
                                 <td>
                                    <paragraph>30 mL</paragraph>
                                 </td>
                                 <td>
                                    <paragraph>                              300 mL</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>After reconstitution, the vials may be stored in a refrigerator for 14 days without significant loss of potency.</paragraph>
                        <paragraph>
                           <sup>b</sup>Use an infusion solution from the list of the compatible infusion solutions below <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_4424e363-f6e5-4fe6-8859-917316741948">Dosage and Administration (2.6)</linkHtml>]</content>.</paragraph>
                        <paragraph>The desired dose diluted in this manner should be administered by intermittent IV infusion over a period of 60 minutes or greater.<br/>
                        </paragraph>
                        <paragraph>Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever solution and container permit.<br/>
                        </paragraph>
                        <paragraph>Discard reconstituted and diluted solutions 14 days after initial reconstitution.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4424e363-f6e5-4fe6-8859-917316741948">
                     <id root="e39bc70f-d05d-4eda-86ec-cfb4ffc51ebb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.6 Compatibility with Intravenous Fluids</content>
                     </title>
                     <text>
                        <paragraph>The following diluents are physically and chemically compatible with 5 g/L vancomycin hydrochloride:</paragraph>
                        <paragraph>5% Dextrose Injection, USP</paragraph>
                        <paragraph>5% Dextrose Injection and </paragraph>
                        <paragraph>0.9% Sodium Chloride Injection, USP</paragraph>
                        <paragraph>Lactated Ringer’s Injection, USP</paragraph>
                        <paragraph>Lactated Ringer’s and 5% Dextrose Injection, USP </paragraph>
                        <paragraph>0.9% Sodium Chloride Injection, USP</paragraph>
                        <paragraph>
                           <content styleCode="underline">Storage of Diluted Solutions:</content>
                        </paragraph>
                        <paragraph>Solutions that are diluted with 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP may be stored in a refrigerator for 14 days without significant loss of potency.</paragraph>
                        <paragraph>Solutions that are diluted with the following infusion fluids may be stored in a refrigerator for 96 hours:</paragraph>
                        <paragraph>5% Dextrose Injection and 0.9% Sodium Chloride Injection, USP</paragraph>
                        <paragraph>Lactated Ringer’s Injection, USP</paragraph>
                        <paragraph>Lactated Ringer’s and 5% Dextrose Injection, USP</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_01cf28eb-ebdd-4593-9610-d2c25b447a95">
                     <id root="ddaa9bc0-3890-41ad-a711-85d4301420a6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.7 Incompatibilities for Intravenous Use</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin solution has a low pH and may cause chemical or physical instability when it is mixed with other compounds.</paragraph>
                        <paragraph>Mixtures of solutions of vancomycin and beta-lactam antibacterial drugs have been shown to be physically incompatible. The likelihood of precipitation increases with higher concentrations of vancomycin. It is recommended to adequately flush the intravenous lines between the administration of these antibacterial drugs. It is also recommended to dilute solutions of vancomycin to 5 mg/mL or less.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_453db056-8e5b-4a49-b3b1-e8b4f8ebef3d">
               <id root="eac040c1-2969-4332-b182-ed1ff242d4b9"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Vancomycin Hydrochloride for Injection, USP is a sterile lyophilized powder for injection supplied as an off-white to light tan colored plug or powder in single-dose vials containing vancomycin hydrochloride, USP equivalent to 1.25 g, or 1.5 g of vancomycin base.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Vancomycin Hydrochloride for Injection is a sterile lyophilized powder for injection in single-dose vials containing vancomycin hydrochloride, USP equivalent to 1.25 g, or 1.5 g of vancomycin base (<linkHtml href="#LINK_453db056-8e5b-4a49-b3b1-e8b4f8ebef3d">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">
               <id root="e4811670-dd5d-432c-b28c-25a219716098"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>Vancomycin hydrochloride for injection is contraindicated in patients with known hypersensitivity to vancomycin.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to vancomycin (<linkHtml href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_f73e3b6b-e858-46c7-96ed-1edbbce99943">
               <id root="dbfc8181-2184-495f-b210-9a8266bc25f8"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 WARNINGS AND PRECAUTIONS</content>
               </title>
               <text/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="underline">Infusion Reactions</content>: Hypotension, including shock and cardiac arrest, wheezing, dyspnea, urticaria, muscular, chest pain and “vancomycin infusion reaction” which manifests as pruritus and erythema that involves the face, neck and upper torso may occur with rapid intravenous administration. To reduce the risk of infusion reactions, administer vancomycin hydrochloride for injection in a diluted solution over a period of 60 minutes or greater and also prior to intravenous anesthetic agents. (<linkHtml href="#LINK_0da61447-6b4f-4927-bdf0-b8af6404cc55">2.1</linkHtml>, <linkHtml href="#LINK_e2101373-36c3-4ee8-894f-dc3993354b7a">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Nephrotoxicity</content>: Systemic vancomycin exposure may result in acute kidney injury (AKI) including acute renal failure, mainly due to interstitial nephritis or less commonly acute tubular necrosis. Monitor serum vancomycin concentrations and renal function. (<linkHtml href="#LINK_69e92b7d-3583-4171-867d-e3869579b9c6">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Ototoxicity</content>: Ototoxicity has occurred in patients receiving vancomycin hydrochloride. Monitor for signs and symptoms of ototoxicity during therapy. Monitor serum vancomycin concentrations and renal function. Assessment of auditory function may be appropriate in some instances. (<linkHtml href="#LINK_fc6dda3f-293a-4921-a87f-bbeb1f2729b4">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Severe Dermatologic Reactions:</content> Discontinue vancomycin hydrochloride for injection at the first appearance of skin rashes, mucosal lesions, or blisters (<linkHtml href="#LINK_ff8a68de-8ab2-4adf-a20d-1b48001f0d44">5.4</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">
                                 <content styleCode="underline">Clostridioides difficile-</content>
                              </content>
                              <content styleCode="underline">Associated Diarrhea</content>: Evaluate patients if diarrhea occurs. (<linkHtml href="#LINK_7d910e2b-e11d-4e9a-8bb9-c5ea88c983f8">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Neutropenia</content>: Periodically monitor leukocyte count. (<linkHtml href="#LINK_9854f54c-e912-45da-831f-1676140466d8">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Phlebitis:</content> To reduce the risk of local irritation and phlebitis administer vancomycin hydrochloride for injection by a secure intravenous route of administration. (<linkHtml href="#LINK_5ac76dfd-5b9a-4154-a902-88a36d5afd1f">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Development of Drug-Resistant Bacteria:</content> Prescribing vancomycin hydrochloride for injection in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria. (<linkHtml href="#LINK_59db17d3-c6d4-428e-b2db-ee9a871a17a0">5.9</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_e2101373-36c3-4ee8-894f-dc3993354b7a">
                     <id root="ef198d0a-6a29-4482-8b61-2b01465b5c92"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 Infusion Reactions</content>
                     </title>
                     <text>
                        <paragraph>Hypotension, including shock and cardiac arrest, wheezing, dyspnea, urticaria, muscular and chest pain may occur with rapid vancomycin hydrochloride for injection administration. The reactions may be more severe in younger patients, particularly children, and in patients receiving concomitant muscle relaxant anesthetics.</paragraph>
                        <paragraph>Rapid intravenous administration of vancomycin hydrochloride for injection may also be associated with “vancomycin infusion reaction”, which manifests as pruritus and erythema that involves the face, neck and upper torso.</paragraph>
                        <paragraph>Infusion-related adverse reactions are related to both the concentration and the rate of administration of vancomycin. Infusion-related adverse reactions may occur, however, at any rate or concentration.</paragraph>
                        <paragraph>Administer vancomycin hydrochloride for injection in a diluted solution over a period of 60 minutes or greater to reduce the risk of infusion-related adverse reactions. In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used; use of such higher concentrations may increase the risk of infusion-related adverse reactions. Administer prior to intravenous anesthetic agents when feasible. Stop the infusion if a reaction occurs.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_69e92b7d-3583-4171-867d-e3869579b9c6">
                     <id root="1c7f6559-bf46-4fdc-9da2-3919647742bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 Nephrotoxicity</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection can result in acute kidney injury (AKI), including acute renal failure, mainly due to interstitial nephritis or less commonly acute tubular necrosis. AKI is manifested by increasing blood urea nitrogen (BUN) and serum creatinine (Cr). The risk of AKI increases with higher vancomycin serum levels, prolonged exposure, concomitant administration of other nephrotoxic drugs, concomitant administration of piperacillin-tazobactam <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_b2744c6a-3789-4c4a-9a7d-e3d031278fee">Drug Interactions (7.2)</linkHtml>]</content>, volume depletion, pre-existing renal impairment and in critically ill patients and patients with co-morbid conditions that predispose to renal impairment.</paragraph>
                        <paragraph> Monitor serum vancomycin concentrations and renal function in all patients receiving vancomycin hydrochloride for injection. More frequent monitoring is recommended in patients with comorbidities that predispose to impairment in renal function or are concomitantly receiving other nephrotoxic drugs, in critically ill patients, in patients with changing renal function, and in patients requiring higher therapeutic vancomycin levels. If acute kidney injury occurs, discontinue vancomycin hydrochloride for injection or reduce the dose.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_fc6dda3f-293a-4921-a87f-bbeb1f2729b4">
                     <id root="0e9642b5-f4eb-4391-b221-43378c524a72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3 Ototoxicity</content>
                     </title>
                     <text>
                        <paragraph>Ototoxicity has occurred in patients receiving vancomycin hydrochloride for injection. It may be transient or permanent. Ototoxicity manifests as tinnitus, hearing loss, dizziness or vertigo. The risk is higher in older patients, patients who are receiving higher doses, who have an underlying hearing loss, who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside or who have underlying renal impairment. Monitor for signs and symptoms of ototoxicity during therapy. Monitor serum vancomycin concentrations and renal function in all patients receiving parenteral vancomycin. Discontinue vancomycin hydrochloride for injection if ototoxicity occurs. Dosage of vancomycin hydrochloride for injection must be adjusted for patients with renal impairment <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_8a3d22c7-1ec1-4174-ba90-3a24d19d439a">Dosage and Administration (2.3)</linkHtml>]</content>. Serial tests of auditory function may be helpful in order to minimize the risk of ototoxicity.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ff8a68de-8ab2-4adf-a20d-1b48001f0d44">
                     <id root="27f481bf-4917-4ec9-a3f9-5d748e3da663"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4 Severe Dermatologic Reactions</content>
                     </title>
                     <text>
                        <paragraph>Severe dermatologic reactions such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and linear IgA bullous dermatosis (LABD) have been reported in association with the use of vancomycin. Cutaneous signs or symptoms reported include skin rashes, mucosal lesions, and blisters.</paragraph>
                        <paragraph>Discontinue vancomycin hydrochloride for injection at the first appearance of signs and symptoms of TEN, SJS, DRESS, AGEP, or LABD.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7d910e2b-e11d-4e9a-8bb9-c5ea88c983f8">
                     <id root="d0e2d19f-4333-40ae-ab0e-6756e91d1abc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5 <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile-</content>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including vancomycin hydrochloride for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile </content>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile </content>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                        <paragraph>Clinically significant serum concentrations have been reported in some patients being treated for active <content styleCode="italics">C. difficile</content>-induced pseudomembranous colitis after multiple oral doses of vancomycin.</paragraph>
                        <paragraph> Prolonged use of vancomycin hydrochloride for injection may result in the overgrowth of nonsusceptible microorganisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. In rare instances, there have been reports of pseudomembranous colitis due to <content styleCode="italics">C. difficile </content>developing in patients who received intravenous vancomycin hydrochloride for injection.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ab46461c-63a7-43a6-82e6-0dcba1bf101c">
                     <id root="03f5a6cc-970d-4b8f-aeef-c3b7ff3d8b5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.6 Hemorrhagic Occlusive Retinal Vasculitis (HORV)</content>
                     </title>
                     <text>
                        <paragraph>Hemorrhagic occlusive retinal vasculitis, including permanent loss of vision, occurred in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery. The safety and efficacy of vancomycin administered by the intracameral or the intravitreal route have not been established by adequate and well-controlled trials. Vancomycin is not indicated for the prophylaxis of endophthalmitis.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9854f54c-e912-45da-831f-1676140466d8">
                     <id root="a24fb670-2c0a-4c65-ae54-3c6a4146339c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.7 Neutropenia</content>
                     </title>
                     <text>
                        <paragraph>Reversible neutropenia has been reported in patients receiving vancomycin hydrochloride for injection <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_83df8d85-6787-48b9-98c0-f3e07bb0dffa">Adverse Reactions (6.1)</linkHtml>]</content>. Patients who will undergo prolonged therapy with vancomycin hydrochloride for injection or those who are receiving concomitant drugs which may cause neutropenia should have periodic monitoring of the leukocyte count.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5ac76dfd-5b9a-4154-a902-88a36d5afd1f">
                     <id root="b03c8f44-0eca-447c-ac35-68e64af29138"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.8 Phlebitis and Other Administration Site Reactions</content>
                     </title>
                     <text>
                        <paragraph>Inflammation at the site of injection of vancomycin hydrochloride for injection has been reported. Vancomycin hydrochloride for injection is irritating to tissue and must be given by a secure intravenous route of administration to reduce the risk of local irritation and phlebitis.</paragraph>
                        <paragraph>Administration of vancomycin hydrochloride for injection by intramuscular (IM), intraperitoneal, intrathecal (intralumbar or intraventricular), or intravitreal routes has not been approved and is not recommended. The safety and efficacy of vancomycin administered by the intrathecal (intralumbar or intraventricular) route or by the intraperitoneal route have not been established by adequate and well controlled trials.</paragraph>
                        <paragraph>Pain, tenderness, and necrosis occur with IM injection of vancomycin hydrochloride for injection or with inadvertent extravasation. Thrombophlebitis may occur, the frequency and severity of which can be minimized by administering the drug slowly as a dilute solution (2.5 to 5 g/L) and by rotation of venous access sites.</paragraph>
                        <paragraph>Intraperitoneal administration during continuous ambulatory peritoneal dialysis (CAPD) can result in chemical peritonitis. Manifestations range from cloudy dialysate alone to a cloudy dialysate accompanied by variable degrees of abdominal pain and fever. This syndrome appears to be resolve after discontinuation of intraperitoneal vancomycin.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_59db17d3-c6d4-428e-b2db-ee9a871a17a0">
                     <id root="1ee1252a-ab4c-4ded-b870-4ee83c8deea0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.9 Development of Drug-Resistant Bacteria</content>
                     </title>
                     <text>
                        <paragraph>Prescribing vancomycin hydrochloride for injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">
               <id root="6603db05-1051-4d2d-8b0a-001a16af763d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Infusion Reactions <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_e2101373-36c3-4ee8-894f-dc3993354b7a">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Nephrotoxicity <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_69e92b7d-3583-4171-867d-e3869579b9c6">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Ototoxicity <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_fc6dda3f-293a-4921-a87f-bbeb1f2729b4">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_7d910e2b-e11d-4e9a-8bb9-c5ea88c983f8">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Hemorrhagic Occlusive Retinal Vasculitis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_ab46461c-63a7-43a6-82e6-0dcba1bf101c">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Neutropenia <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_9854f54c-e912-45da-831f-1676140466d8">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The common adverse reactions are anaphylaxis, “vancomycin infusion reaction”, acute kidney Injury, hearing loss, neutropenia. (<linkHtml href="#LINK_83df8d85-6787-48b9-98c0-f3e07bb0dffa">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <linkHtml href="https://nam04.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;data=05%7C01%7Ccneff%40hikma.com%7Cd2d3fc2925b9427a8e6a08da65b22083%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C0%7C637934112958299579%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=ZHNDtXEH8XDmuiivZWRCb7AdlRtGAg%2BPQzEj8%2B8bsec%3D&amp;reserved=0">www.fda.gov/medwatch</linkHtml>
                              </content>
                           </content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_83df8d85-6787-48b9-98c0-f3e07bb0dffa">
                     <id root="915fc542-adec-4f6c-b235-710bb2886b13"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The following adverse reactions associated with the use of vancomycin hydrochloride for injection were identified in clinical trials:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders: </content>Hypersensitivity reactions including anaphylaxis and “vancomycin infusion reaction” <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_e2101373-36c3-4ee8-894f-dc3993354b7a">Warnings and Precautions (5.1)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders: </content>Erythema (especially of the face, neck and upper torso) and pruritus which are manifestations of rashes including exfoliative dermatitis, toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), Linear IgA bullous dermatosis (LABD) <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_ff8a68de-8ab2-4adf-a20d-1b48001f0d44">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and urinary disorders: </content>Acute kidney injury and interstitial nephritis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ear and Labyrinth Disorders: </content>Tinnitus, hearing loss, vertigo</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and Lymphatic System Disorders: </content>Agranulocytosis, neutropenia, pancytopenia, leukopenia, thrombocytopenia, eosinophilia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders: </content>Pseudomembranous colitis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_7d910e2b-e11d-4e9a-8bb9-c5ea88c983f8">Warnings and Precautions (5.5)</linkHtml>] </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders: </content>Cardiac arrest, chest pain</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions: </content>General discomfort, fever, chills, phlebitis, injection site irritation, injection site pain and necrosis following intramuscular injection, chemical peritonitis following intraperitoneal administration</paragraph>
                        <paragraph>(Vancomycin hydrochloride for injection is not approved for intramuscular and intraperitoneal administration) <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_9854f54c-e912-45da-831f-1676140466d8">Warnings and Precautions (5.7)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Laboratory Abnormalities: </content>Elevated blood urea nitrogen, elevated serum creatinine</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and connective tissue disorders: </content>Muscle pain</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders: </content>Dizziness</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, thoracic and mediastinal disorders: </content>Wheezing, dyspnea</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular disorders: </content>Hypotension, shock, vasculitis</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3dca56ad-fea3-4904-8460-fa3424cce55b">
                     <id root="60c8390f-59e3-4c39-914d-2a2dc10f57f5"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2 Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of vancomycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders</content>: Drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_ff8a68de-8ab2-4adf-a20d-1b48001f0d44">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_17266c45-cb57-428f-9e0a-08815b20594d">
               <id root="2ebd7931-c8fe-4ee9-835d-0038db3a35aa"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7 DRUG INTERACTIONS</content>
               </title>
               <text>
                  <paragraph>Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing <content styleCode="italics">[see Warnings and Precautions (5.1) </content>and <content styleCode="italics">Use in Specific Populations (8.4)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="underline">Anesthetic Agents</content>: Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing. (<linkHtml href="#LINK_0da61447-6b4f-4927-bdf0-b8af6404cc55">2.1</linkHtml>, <linkHtml href="#LINK_3b0d2d86-84cb-47c2-b401-2005f0f579f8">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Piperacillin/Tazobactam:</content> Increased incidence of acute kidney injury in patients receiving concomitant piperacillin/tazobactam and vancomycin as compared to vancomycin alone. Monitor kidney function in patients (<linkHtml href="#LINK_b2744c6a-3789-4c4a-9a7d-e3d031278fee">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_3b0d2d86-84cb-47c2-b401-2005f0f579f8">
                     <id root="4d2bae5a-7cb7-48fc-b0e7-4ada4ffa56ca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1 Anesthetic Agents</content>
                     </title>
                     <text>
                        <paragraph>Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_e2101373-36c3-4ee8-894f-dc3993354b7a">Warnings and Precautions (5.1)</linkHtml> </content>and <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_2de9de63-7015-4729-94e1-92c1738623fa">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b2744c6a-3789-4c4a-9a7d-e3d031278fee">
                     <id root="5e3c3f63-7574-4aac-b57f-ee8f5d57242d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2 Piperacillin-Tazobactam</content>
                     </title>
                     <text>
                        <paragraph>Studies have detected an increased incidence of acute kidney injury in patients administered concomitant piperacillin/tazobactam and vancomycin as compared to vancomycin alone. Monitor kidney function in patients receiving concomitant piperacillin/tazobactam and vancomycin. No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_092f0314-c927-4814-a7a0-c817a94ec0d6">
                     <id root="77804b4c-8dbd-47e5-9e8b-379a50de1083"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.3 Ototoxic and/or Nephrotoxic Drugs</content>
                     </title>
                     <text>
                        <paragraph>Concurrent and/or sequential systemic or topical use of other potentially, neurotoxic and/or nephrotoxic drugs requires more frequent monitoring of renal function.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4131ba19-89d3-477d-85da-29cf4941d0e0">
               <id root="acbbbaed-769a-4e9c-a194-76122fbaebbd"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 USE IN SPECIFIC POPULATIONS</content>
               </title>
               <text/>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LINK_3d64c32b-83e1-4932-925c-bf3fae007911">
                     <id root="a40c3239-22f6-43ae-a285-8987b1fa1c3c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on vancomycin use in pregnant women to inform a drug associated risk of major birth defects or miscarriage. Available published data on vancomycin use in pregnancy during the second and third trimesters have not shown an association with adverse pregnancy related outcomes <content styleCode="italics">(see Data)</content>. Vancomycin did not show adverse developmental effects when administered intravenously to pregnant rats and rabbits during organogenesis at doses less than or equal to the recommended maximum human dose based on body surface area <content styleCode="italics">(see Data)</content>.</paragraph>
                        <paragraph>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>A published study evaluated hearing loss and nephrotoxicity in infants of pregnant intravenous drug users treated with vancomycin for suspected or documented methicillin-resistant <content styleCode="italics">Staphylococcus-aureus </content>in the second or third trimester. The comparison groups were 10 non-intravenous drug-dependent patients who received no treatment, and 10 untreated intravenous drug-dependent patients who served as substance abuse controls. No infant in the vancomycin exposed group had abnormal sensorineural hearing at 3 months of age or nephrotoxicity.<br/>
                        </paragraph>
                        <paragraph>A published prospective study assessed outcomes in 55 pregnant women with a positive Group B streptococcus (GBS) culture and a high-risk penicillin allergy with resistance to clindamycin or unknown sensitivity who were administered vancomycin at the time of delivery. Vancomycin dosing ranged from the standard 1 g intravenously every 12 hours to 20 mg/kg intravenous every 8 hours (maximum individual dose 2 g). No major adverse reactions were recorded either in the mothers or their newborns. None of the newborns had sensorineural hearing loss. Neonatal renal function was not examined, but all of the newborns were discharged in good condition.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Vancomycin did not cause fetal malformations when administered during organogenesis to pregnant rats (gestation days 6 to 15) and rabbits (gestation days 6 to 18) at the equivalent recommended maximum human dose (based on body surface area comparisons) of 200 mg/kg/day IV to rats or 120 mg/kg/day IV to rabbits. No effects on fetal weight or development were seen in rats at the highest dose tested or in rabbits given 80 mg/kg/day (approximately 1 and 0.8 times the recommended maximum human dose based on body surface area, respectively). Maternal toxicity was observed in rats (at doses 120 mg/kg and above) and rabbits (at 80 mg/kg and above).</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a0c09a93-b948-4421-9330-cc907ba47d24">
                     <id root="c508988c-a64c-4a68-a0aa-3d3a51e7edcb"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are insufficient data to inform the levels of vancomycin in human milk. There are no data on the effects of vancomycin on the breastfed infant or milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for vancomycin and any potential adverse effects on the breastfed infant from vancomycin or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2de9de63-7015-4729-94e1-92c1738623fa">
                     <id root="36b55206-fd0a-4c93-b8f7-6daa8eeaf94b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection is indicated in pediatric patients (neonates and older). In pediatric patients, monitor vancomycin serum concentration and renal function when administering vancomycin hydrochloride for injection <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_72f5c693-5c78-4203-8149-1c67678ab3af">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#www.splportal.comLINK_8a3d22c7-1ec1-4174-ba90-3a24d19d439a">2.3</linkHtml>) </content>and <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_69e92b7d-3583-4171-867d-e3869579b9c6">Warnings and Precautions (5.2)</linkHtml>]</content>. More severe infusion related reactions related to vancomycin administration may occur in pediatric patients. Concomitant administration of vancomycin and intravenous anesthetic agents has been associated with erythema and histamine-like flushing in all patients including pediatric patients <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_e2101373-36c3-4ee8-894f-dc3993354b7a">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">
                     <id root="239a1078-b7a4-4583-a486-f1f3f2d54650"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin hydrochloride for injection is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_72f5c693-5c78-4203-8149-1c67678ab3af">Dosage and Administration (2.2)</linkHtml>]</content>, and it may be useful to monitor renal function <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_69e92b7d-3583-4171-867d-e3869579b9c6">Warnings and Precautions (5.2)</linkHtml>]</content>.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_76922bd7-15a9-47b4-9eed-781a842e50c2">
               <id root="8955228b-14de-429f-8713-506645669fe7"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>Supportive care is advised, with maintenance of glomerular filtration. Vancomycin is poorly removed by dialysis. Hemofiltration and hemoperfusion with polysulfone resin have been reported to result in increased vancomycin clearance.</paragraph>
                  <paragraph>For current information on the management of overdosage, contact the National Poison Control Center at 1-800-222-1222 or <linkHtml href="http://www.poison.org/">www.poison.org</linkHtml>.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section ID="LINK_270240c8-24da-44ce-af8d-3341abaa6a73">
               <id root="49a9411b-3264-43f9-9817-a2865bfa40bc"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Vancomycin Hydrochloride for Injection, USP, contains the hydrochloride salt of vancomycin, a tricyclic glycopeptide antibacterial derived from <content styleCode="italics">Amycolatopsis orientalis </content>(formerly <content styleCode="italics">Nocardia orientalis</content>). The chemical name for vancomycin hydrochloride, USP is (Sa)- (3<content styleCode="italics">S</content>,6<content styleCode="italics">R</content>,7<content styleCode="italics">R</content>,22<content styleCode="italics">R</content>,23<content styleCode="italics">S</content>,26<content styleCode="italics">S</content>,36<content styleCode="italics">R</content>,38a<content styleCode="italics">R</content>)-44-[[2-<content styleCode="italics">O</content>-(3-Amino-2,3,6-trideoxy-3-<content styleCode="italics">C</content>-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy]-3-(carbamoylmethyl)-10,19-dichloro- 2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-[(2<content styleCode="italics">R</content>)-4- methyl-2-(methylamino)valeramido]-2,5,24,38,39-pentaoxo-22<content styleCode="italics">H</content>-8,11:18,21-dietheno-23,36- (iminomethano)-13,16:31,35-dimetheno-1<content styleCode="italics">H</content>,16<content styleCode="italics">H</content>-[l,6,9]oxadiazacyclohexadecino[4,5- m][10,2,16]-benzoxadiazacyclotetracosine-26-carboxylic acid, monohydrochloride. The molecular formula is C<sub>66</sub>H<sub>75</sub>Cl<sub>2</sub>N<sub>9</sub>O<sub>24</sub> • HCl and the molecular weight is 1,485.71. Vancomycin hydrochloride, USP has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Vancomycin Hydrochloride for Injection, USP is a sterile off-white to light tan colored lyophilized plug or powder for injection. Vancomycin Hydrochloride for Injection, USP is supplied in single- dose vials, containing, 1.28 g, or 1.54 g of vancomycin hydrochloride, USP equivalent to, 1.25 g, or 1.5 g of vancomycin base. The lyophilized powder is reconstituted with Sterile Water for Injection, USP which forms a clear, colorless or light to dark tan solution and subsequently diluted prior to intravenous administration <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_7c26d99c-9549-4eb7-9392-3298280aa787">Dosage and Administration (2.5)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vancomycin-hydrochloride-for-injection-usp-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b2e74910-6622-4ed1-8296-a59406ca0f2a">
               <id root="e0ffb09e-6ab6-4dfe-a540-50e99fb6f19a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LINK_44e3e2c1-4e9c-49f3-9f4a-ae93ab70f634">
                     <id root="834d6c1b-5069-4820-bef3-03556298e42d"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Vancomycin is an antibacterial drug <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_cf5f89c0-18dd-41a1-a568-6cc369b11f68">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1a08c30c-33d2-4898-b57c-8dd379621245">
                     <id root="e4dd7e61-48d7-46cd-95eb-dde0cdd60b9b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2 Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>The pharmacodynamics of vancomycin is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">
                     <id root="673005c0-13d2-478d-b8aa-19015889fb2c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion of infusion, mean plasma concentrations of approximately 23 mcg/mL 2 hours after infusion, and mean plasma concentrations of approximately 8 mcg/mL 11 hours after the end of the infusion. Multiple dosing of 500 mg infused over 30 minutes produces mean plasma concentrations of about 49 mcg/mL at the completion of infusion, mean plasma concentrations of about 19 mcg/mL 2 hours after infusion, and mean plasma concentrations of about 10 mcg/mL 6 hours after infusion. The plasma concentrations during multiple dosing are like those after a single dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The volume of distribution ranges from 0.3 to 0.43 L/kg after intravenous administration. Vancomycin is approximately 55% serum protein bound as measured by ultrafiltration at vancomycin serum concentrations of 10 to 100 mcg/mL. After intravenous administration of vancomycin, inhibitory concentrations are present in pleural, pericardial, ascitic, and synovial fluids; in urine; in peritoneal dialysis fluid; and in atrial appendage tissue. Vancomycin does not readily diffuse across normal meninges into the spinal fluid; but, when the meninges are inflamed, penetration into the spinal fluid occurs.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Mean plasma clearance is about 0.058 L/kg/h, and mean renal clearance is about 0.048 L/kg/h. The mean elimination half-life of vancomycin from plasma is 4 to 6 hours in subjects with normal renal function. In anephric patients, the mean elimination half-life is 7.5 days. Total body and renal clearance of vancomycin may be reduced in the elderly.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>There is no apparent metabolism of the vancomycin.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>In the first 24 hours after intravenous administration, about 75% of an administered dose of vancomycin is excreted in urine by glomerular filtration. Renal impairment slows excretion of vancomycin.<br/>
                        </paragraph>
                        <paragraph>About 60% of an intraperitoneal dose of vancomycin administered during peritoneal dialysis is absorbed systemically in 6 hours. Serum concentrations of about 10 mcg/mL are achieved by intraperitoneal injection of 30 mg/kg of vancomycin. However, the safety and efficacy of the intraperitoneal use of vancomycin has not been established in adequate and well-controlled trials <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_9854f54c-e912-45da-831f-1676140466d8">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cf5f89c0-18dd-41a1-a568-6cc369b11f68">
                     <id root="1e04946d-bfbb-495b-a7f3-c77a57c6090d"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>
                        <content styleCode="bold">12.4 Microbiology</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance</content>
                           <br/>
                        </paragraph>
                        <paragraph>Vancomycin is not active <content styleCode="italics">in vitro </content>against gram-negative bacilli, mycobacteria, or fungi. There is no cross-resistance between vancomycin and other antibacterials.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Interaction With Other Antimicrobials</content>
                        </paragraph>
                        <paragraph>The combination of vancomycin and an aminoglycoside acts synergistically <content styleCode="italics">in vitro </content>against many isolates of <content styleCode="italics">Staphylococcus aureus</content>, <content styleCode="italics">Streptococcus gallolyticus (</content>previously known as <content styleCode="italics">Streptococcus bovis)</content>, enterococcus spp, and the viridans group streptococci.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <paragraph>Vancomycin has been shown to be active against most isolates of the following microorganisms, both <content styleCode="italics">in vitro </content>and in clinical infections <content styleCode="italics">[see I<linkHtml href="#www.splportal.comLINK_89e216a7-8b92-49d4-ada0-96ac04abc313">ndications and Usage (1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Aerobic Gram-Positive Bacteria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Corynebacterium </content>spp.<br/>
                        </paragraph>
                        <paragraph>Enterococcus spp. (including <content styleCode="italics">Enterococcus faecalis</content>)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus aureus </content>(including methicillin-resistant and methicillin-susceptible isolates)</paragraph>
                        <paragraph>Coagulase negative staphylococci (including <content styleCode="italics">S. epidermidis </content>and methicillin-resistant isolates)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus gallolyticus (</content>previously known as <content styleCode="italics">Streptococcus bovis)</content>
                        </paragraph>
                        <paragraph>Viridans group streptococci</paragraph>
                        <paragraph>The following <content styleCode="italics">in vitro </content>data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an <content styleCode="italics">in vitro </content>minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for vancomycin against isolates of similar genus or organism group. However, the efficacy of vancomycin in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Aerobic Gram-Positive Bacteria </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                           <content styleCode="italics">Listeria monocytogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus pyogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus pneumoniae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus agalactiae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Anaerobic Gram-Positive Bacteria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Actinomyces </content>species</paragraph>
                        <paragraph>
                           <content styleCode="italics">Lactobacillus </content>species</paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Susceptibility Testing</content>
                           </content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https:<linkHtml href="http://www.fda.gov/STIC">//www.fda.gov/STIC.</linkHtml>
                           <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                     <excerpt>
                        <highlight>
                           <text>
                              <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride for injection and other antibacterial drugs, vancomycin hydrochloride for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (<linkHtml href="#LINK_921baa67-d1b3-4cff-b82d-db170b788095">1.6</linkHtml>)<br/>
                              </paragraph>
                           </text>
                        </highlight>
                     </excerpt>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_17d4e9cd-7b7f-4bc1-9322-9c34024eea7b">
               <id root="33da33de-df3f-4511-9f41-081ab0160197"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LINK_808a0b7e-82d1-4e86-a48b-49a6a789972e">
                     <id root="5328bb0f-cbb9-4373-98c4-9963278c4b37"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Although no long-term studies in animals have been performed to evaluate carcinogenic potential, no mutagenic potential of vancomycin hydrochloride for injection was found in standard laboratory tests. No definitive fertility studies have been performed.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5db87c74-a8b2-48e6-84c5-01dd8fb44315">
                     <id root="6e47e03d-6f71-414f-8018-e0b635794370"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>
                        <content styleCode="bold">13.2 Animal Toxicology and/or Pharmacology</content>
                     </title>
                     <text>
                        <paragraph>In animal studies, hypotension and bradycardia occurred in dogs receiving an intravenous infusion of vancomycin hydrochloride 25 mg/kg, at a concentration of 25 mg/mL and an infusion rate of 13.3 mL/min.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ef22eaa2-7142-43a1-8455-da7d368f393d">
               <id root="3974b065-b87a-4434-b6f6-648322aecfe1"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>
                  <content styleCode="bold">15 REFERENCES</content>
               </title>
               <text>
                  <paragraph>1. Byrd RA., Gries CL, Buening M.: Developmental Toxicology Studies of Vancomycin Hydrochloride Administered Intravenously to Rats and Rabbits. Fundam Appl Toxicol 1994; 23: 590-597.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section ID="LINK_dd887705-9ac2-46cb-9de4-1970f5ede59c">
               <id root="53d0af77-bf76-4086-a330-491d0013646f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 HOW SUPPLIED/STORAGE AND HANDELING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied:</content>
                  </paragraph>
                  <paragraph>Vancomycin Hydrochloride for Injection, USP is a sterile lyophilized powder for injection supplied as an off-white to light tan colored powder or plug in single-dose flip top vials that contain vancomycin hydrochloride, USP equivalent to 1.25 g, or 1.5 g of vancomycin base. They are available as follows:</paragraph>
                  <paragraph>NDC  0143-9152-10: Vancomycin Hydrochloride for Injection, USP equivalent to 1.25 g vancomycin in a 50 mL flip top vial with a light violet seal, in packages of 10 vials.</paragraph>
                  <paragraph>NDC  0143-9153-10: Vancomycin Hydrochloride for Injection, USP equivalent to 1.5 g vancomycin in a 50 mL flip top vial with a white seal, in packages of 10 vials.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage:</content>
                  </paragraph>
                  <paragraph>Prior to reconstitution, store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.]</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section ID="LINK_21f9b8f0-53d0-4958-8d02-627a67f665dd">
               <id root="f101d74c-11a5-491a-b6d4-04beacb661a5"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17 PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Infusion Reactions During or After Intravenous Use</content>
                  </paragraph>
                  <paragraph>Advise patients that generalized skin redness, skin rash, itching, flushing, muscle pain, chest pain, shortness of breath, wheezing, or dizziness may occur during intravenous infusion of vancomycin hydrochloride for injection. These reactions can be lessened or prevented by infusing the drug over at least 60 minutes <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_e2101373-36c3-4ee8-894f-dc3993354b7a">Warnings and Precautions (5.1)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Acute Kidney Injury</content>
                     <br/>
                  </paragraph>
                  <paragraph>Advise patients that vancomycin hydrochloride for injection can result in kidney damage and that blood tests are required to monitor vancomycin blood levels and kidney function during therapy. <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_69e92b7d-3583-4171-867d-e3869579b9c6">Warnings and Precautions (5.2)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hearing Loss or Balance Problems</content>
                     <br/>
                  </paragraph>
                  <paragraph>Advise patients that vancomycin hydrochloride for injection may result in decreased hearing and to report hearing loss or balance problems to their healthcare provider <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_fc6dda3f-293a-4921-a87f-bbeb1f2729b4">Warnings and Precautions (5.3)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Severe Dermatologic Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients about the signs and symptoms of serious skin manifestations. Instruct patients to stop vancomycin hydrochloride for injection immediately and promptly seek medical attention at the first signs or symptoms of skin rash, mucosal lesions or blisters <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_ff8a68de-8ab2-4adf-a20d-1b48001f0d44">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Antibacterial Resistance</content>
                  </paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs including vancomycin hydrochloride for injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When vancomycin hydrochloride for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Vancomycin hydrochloride for injection or other antibacterial drugs in the future. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Diarrhea</content>
                  </paragraph>
                  <paragraph>Diarrhea is a common problem caused by antibacterial drugs, including vancomycin, which usually ends when the antibacterial drug is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_7d910e2b-e11d-4e9a-8bb9-c5ea88c983f8">Warnings and Precautions (5.5)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>The brands listed are trademarks of their respective owners.<br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>HIKMA FARMACÊUTICA (PORTUGAL), S.A.</paragraph>
                  <paragraph>Estrada do Rio da Mó, 8, 8A e 8B – Fervença – 2705-906 Terrugem SNT, PORTUGAL</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>Hikma Pharmaceuticals USA Inc.</paragraph>
                  <paragraph>Berkeley Heights, NJ 07922</paragraph>
                  <paragraph>Revised February 2023</paragraph>
                  <paragraph>PIN624-WES/2</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section ID="LINK_c9e2e2fb-fc19-475c-bdfd-880c03127922">
               <id root="9ea1ab6b-ec46-4732-b7b3-ba93ead58d7c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 1.25 g</content>
               </title>
               <text>
                  <paragraph>NDC 0143-<content styleCode="bold">9152</content>-01         Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Vancomycin Hydrochloride for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1.25 g* per <linkHtml href="#">vial</linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <linkHtml href="#">AFTER RECONSTITUTION MUST BE FURTHER DILUTED. </linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SEE PACKAGE INSERT.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Single-Dose Vial</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>NDC 0143-<content styleCode="bold">9152</content>-10         Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Vancomycin Hydrochloride for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1.25 g* per <linkHtml href="#">vial</linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <linkHtml href="#">AFTER RECONSTITUTION MUST BE FURTHER DILUTED. </linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SEE PACKAGE INSERT.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 x 1.25 g Single-Dose Vials</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM3"/>
                     </content>
                  </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>1.25 g label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vancomycin-hydrochloride-for-injection-usp-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>1.25 g carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vancomycin-hydrochloride-for-injection-usp-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d0976696-6776-44d6-8ad9-b96b8adfd9c4">
               <id root="ec1d57a3-1cd5-498f-a3ae-88506a2ee595"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1.5 g</title>
               <text>
                  <paragraph>NDC 0143-<content styleCode="bold">9153</content>-01         Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Vancomycin Hydrochloride for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1.5 g* per <linkHtml href="#">vial</linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <linkHtml href="#">AFTER RECONSTITUTION MUST BE FURTHER DILUTED. </linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SEE PACKAGE INSERT.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Single-Dose Vial</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph>NDC 0143-<content styleCode="bold">9153</content>-10         Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Vancomycin Hydrochloride for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1.5 g* per <linkHtml href="#">vial</linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <linkHtml href="#">AFTER RECONSTITUTION MUST BE FURTHER DILUTED. </linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SEE PACKAGE INSERT.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 x 1.5 g Single-Dose Vials</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <br/>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>1.5 g label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vancomycin-hydrochloride-for-injection-usp-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>1.5 g carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vancomycin-hydrochloride-for-injection-usp-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>